Skip to main content
Sunshine Biopharma Inc. logo

Sunshine Biopharma Inc. — Investor Relations & Filings

Ticker · SBFM ISIN · US8677817004 LEI · 5299005Y64EHRQDQ2Q25 US Manufacturing
Open in API
Filings indexed 382 across all filing types
Latest filing 2022-02-09 Capital/Financing Update
Country US United States of America
Listing US SBFM

About Sunshine Biopharma Inc.

https://www.sunshinebiopharma.com/

Sunshine Biopharma Inc. is a pharmaceutical company engaged in the research, development, and commercialization of life-saving medicines. The company's primary focus is on various therapeutic areas, with a significant emphasis on oncology and antiviral treatments.

Recent filings

Filing Released Lang Actions
FORM S-1 AMENDMENT 3
Capital/Financing Update Classification · 95% confidence The document is a Form S-1/A (Amendment No. 3) filed with the SEC, which is a registration statement under the Securities Act of 1933. It includes details about the registration fee, exhibits, and signatures but does not contain financial statements or earnings data. The document is related to a securities offering and capital raising activity. This type of filing corresponds to capital/financing updates rather than annual reports, earnings releases, or other categories. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is over 12,000 characters, indicating it is a full filing, not just an announcement or certification.
2022-02-09 English
CURRENT REPORT
Investor Presentation Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated February 7, 2022, by Sunshine Biopharma, Inc. It includes a Regulation FD Disclosure under Item 7.01, stating that attached Exhibit 99.1 is a PowerPoint presentation intended for potential investors. The document explicitly states that the information is not "filed" for purposes of Section 18 and is not incorporated by reference into other filings. The content is a presentation material rather than a full financial report or earnings release. The document length is 3436 characters, which is relatively short and consistent with an investor presentation or announcement rather than a full report. Therefore, the most appropriate classification is Investor Presentation (IP).
2022-02-07 English
FORM S-1 AMENDMENT 2
Capital/Financing Update Classification · 95% confidence The document is a Form S-1/A (Amendment No. 2) registration statement filed with the SEC under the Securities Act of 1933. It is a registration statement for a securities offering by Sunshine Biopharma, Inc., including details about the offering, underwriting, and related legal and financial disclosures. The document is not an annual or quarterly report, audit report, earnings release, or any other financial performance report. Instead, it is a capital raising filing related to the registration of securities for public sale. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed offering information, consistent with a capital raising filing rather than a mere announcement or regulatory filing. Hence, the classification is CAP with high confidence.
2022-02-03 English
AMENDMENT TO FORM S-1
Capital/Financing Update Classification · 95% confidence The document is a Form S-1/A registration statement filed with the SEC, which is used for registering securities for public offering under the Securities Act of 1933. It includes detailed information about the securities being offered, underwriting arrangements, risk factors, business overview, management, and financial statements. This type of filing is related to capital raising activities and financing updates rather than a financial report or earnings release. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it is not merely an announcement or a certification, so it is not RPA or RNS. The presence of underwriting details and offering terms confirms it is a financing update.
2022-01-24 English
DEF 14C
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a DEF 14C filing, which is an Information Statement pursuant to Section 14(c) of the Securities Exchange Act of 1934. It informs shareholders about corporate actions taken by written consent, specifically regarding an increase in the reverse stock split ratio. The document explicitly states it is not soliciting proxies and no shareholder vote is required. It is a communication to shareholders about a corporate action, not a proxy solicitation or voting results announcement. The content is detailed and lengthy (15,000 characters), containing the full information statement text. This matches the definition of a Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings or inform about shareholder actions. It is not an announcement of voting results (DVA), nor a regulatory filing (RNS) or report publication announcement (RPA). Therefore, the correct classification is PSI with high confidence.
2022-01-18 English
Declaration of Voting Results & Voting Rights Announcements 2022
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Schedule 14C Information Statement filed with the SEC, pursuant to Section 14(c) of the Securities Exchange Act of 1934. It informs shareholders about corporate actions taken by written consent, specifically an increase in the reverse stock split ratio. The document explicitly states it is an Information Statement, not a proxy solicitation, and no shareholder vote is required. The content focuses on shareholder notification of corporate governance actions related to capital structure (reverse stock split) and voting results by written consent. This type of document is used to inform shareholders of voting results and corporate actions without a meeting. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length and detail confirm it is not a brief announcement or proxy solicitation but a formal information statement about voting results and corporate action.
2022-01-06 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.